Skip to main content

Table 2 One-way sensitivity analysis of discounted per-patient costs

From: Using decision-analysis modelling to estimate the economic impact of the identification of unrecognised bipolar disorder in primary care: the untapped potential of screening

Sensitivity analysis of discounted costs for patient presenting with new episode of MDD ($*)
Original input parameters Sensitivity analysis No screening Delta Study Savings
Prevalence of UBP in new MDD cases (16%)     
  Low estimate (11%) 49,140 48,622 518
  High estimate (21%) 52,731 50,404 2327
Sensitivity & Specificity (0.76 , 0.87)     
  Low sensitivity, high specificity (0.58, 0.97) 50,936 49,255 1681
  High sensitivity, low specificity (0.92, 0.75) 50,936 50,114 822
Cost of RBP relative to UBP (− 7604)     
  High estimate (150%, − 11,406) 57,424 55,869 1554
  Low estimate (50%, − 3802) 44,448 43,157 1291
Cost of MDD relative to UBP (− 1936)     
  High estimate (150%, − 17,904) 74,718 69,732 4985
  Low estimated (50%, − 5968) 27,154 29,293 − 2139
Cost of RBP relative to MDD (+4332)     
  RBP = MDD 64,919 63,055 1864
Annual probability of diagnosis correction (15%)     
  Low estimate (10%) 51,402 49,758 1644
  High estimate (20%) 50,525 49,297 1228
Probability of psychiatric evaluation (75%)     
  Low estimate (50%) 50,936 50,728 207
  High estimate (100%) 50,936 48,297 2638
  1. RBP: Recognised bipolar disorder patients; MDD: Major depressive disorder; UBP: Unrecognised bipolar disorder patients; CI: Confidence interval
  2. *Discounted costs expressed as 2021 USD